Recent data indicates that retatrutide, a novel medication, could represent a considerable step in body management. This treatment combines the properties of a GLP-1 receptor and a GIP receptor , possibly offering a enhanced outcome than current therapies . Study trials have demonstrated positive outcomes, including significant reductions in weight